{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:35:20Z","timestamp":1784374520782,"version":"3.55.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02660-1","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T14:58:31Z","timestamp":1742309911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nanotechnology in Imatinib delivery: advancing cancer treatment through innovative nanoparticles"],"prefix":"10.1007","volume":"42","author":[{"given":"Azam","family":"Ghadami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Fathi-karkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bazla","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Ashfaq","family":"Gondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Rahdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar Abbaszadeh","family":"Garousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelal","family":"Kharaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Ghotekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"11","key":"2660_CR1","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1007\/s13346-023-01366-z","volume":"13","author":"P Gupta","year":"2023","unstructured":"Gupta P, et al. Lipid-based nanoparticle-mediated combination therapy for breast cancer management: a comprehensive review. Drug Deliv Transl Res. 2023;13(11):2739\u201366.","journal-title":"Drug Deliv Transl Res"},{"key":"2660_CR2","unstructured":"Alam, M.W., Investigating ALK inhibitors alone or in combination as therapeutic options for ALK-positive neuroblastoma. 2021."},{"key":"2660_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125529","volume":"245","author":"S Bhattacharya","year":"2023","unstructured":"Bhattacharya S, et al. Physicochemical characterization, in vitro and in vivo evaluation of chitosan\/carrageenan encumbered with Imatinib mesylate-polysarcosine nanoparticles for sustained drug release and enhanced colorectal cancer targeted therapy. Int J Biol Macromol. 2023;245: 125529.","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"2660_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/17425247.2023.2223941","volume":"20","author":"A Narmani","year":"2023","unstructured":"Narmani A, et al. Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy. Expert Opin Drug Deliv. 2023;20(7):937\u201354.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"2660_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/0113892010284407240212110745","volume":"26","author":"K Sindhi","year":"2025","unstructured":"Sindhi K, Kanugo A. Recent developments in nanotechnology and immunotherapy for the diagnosis and treatment of pancreatic cancer. Curr Pharm Biotechnol. 2025;26(2):143\u201368.","journal-title":"Curr Pharm Biotechnol"},{"key":"2660_CR6","doi-asserted-by":"crossref","unstructured":"McFarland, D.C., L. Blackler, and J. Holland, New challenges to psycho\u2010oncology research: precision medicine oncology and targeted therapies. 2017, Wiley Online Library. p. 144\u2013146.","DOI":"10.1002\/pon.4371"},{"issue":"24","key":"2660_CR7","doi-asserted-by":"publisher","first-page":"7471","DOI":"10.1158\/1078-0432.CCR-09-1070","volume":"15","author":"LM Ellis","year":"2009","unstructured":"Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology. Clin Cancer Res. 2009;15(24):7471\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2660_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/ijms19010210","volume":"19","author":"K Wdowiak","year":"2018","unstructured":"Wdowiak K, et al. Galectin targeted therapy in oncology: current knowledge and perspectives. Int J Mol Sci. 2018;19(1):210.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2660_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa C, et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther. 2024;9(1):201.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2660_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, et al. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther. 2022;7(1):329.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2660_CR11","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/cancers14071832","volume":"14","author":"D van de Wal","year":"2022","unstructured":"van de Wal D, et al. Health-related quality of life and side effects in gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors: a systematic review of the literature. Cancers. 2022;14(7):1832.","journal-title":"Cancers"},{"issue":"1","key":"2660_CR12","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014(1): 357027.","journal-title":"Chemother Res Pract"},{"issue":"13","key":"2660_CR13","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.3390\/cancers13133164","volume":"13","author":"K Khaddour","year":"2021","unstructured":"Khaddour K, et al. Targeting the epidermal growth factor receptor in EGFR-mutated lung cancer: current and emerging therapies. Cancers. 2021;13(13):3164.","journal-title":"Cancers"},{"issue":"12","key":"2660_CR14","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.3390\/ijms22126538","volume":"22","author":"E Russo","year":"2021","unstructured":"Russo E, et al. Nanotechnology of tyrosine kinase inhibitors in cancer therapy: a perspective. Int J Mol Sci. 2021;22(12):6538.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2660_CR15","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1021\/acs.jmedchem.7b00468","volume":"60","author":"Y Lu","year":"2017","unstructured":"Lu Y, et al. Discovery of potent, selective stem cell factor receptor\/platelet derived growth factor receptor alpha (c-KIT\/PDGFR\u03b1) dual inhibitor for the treatment of Imatinib-resistant gastrointestinal stromal tumors (GISTs). J Med Chem. 2017;60(12):5099\u2013119.","journal-title":"J Med Chem"},{"issue":"8","key":"2660_CR16","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1007\/s13277-016-5069-z","volume":"37","author":"K Appiah-Kubi","year":"2016","unstructured":"Appiah-Kubi K, et al. Platelet-derived growth factor receptor\/platelet-derived growth factor (PDGFR\/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers. Tumor Biol. 2016;37(8):10053\u201366.","journal-title":"Tumor Biol"},{"key":"2660_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1208\/s12249-015-0384-z","volume":"17","author":"B Gupta","year":"2016","unstructured":"Gupta B, et al. Effects of formulation variables on the particle size and drug encapsulation of Imatinib-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2016;17:652\u201362.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"2660_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1567201811666140822112516","volume":"12","author":"V Jain","year":"2015","unstructured":"Jain V, Jain S, Mahajan S. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment. Curr Drug Deliv. 2015;12(2):177\u201391.","journal-title":"Curr Drug Deliv"},{"issue":"5","key":"2660_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7010","volume":"13","author":"A Manzari-Tavakoli","year":"2024","unstructured":"Manzari-Tavakoli A, et al. Integrating natural compounds and nanoparticle-based drug delivery systems: a novel strategy for enhanced efficacy and selectivity in cancer therapy. Cancer Med. 2024;13(5): e7010.","journal-title":"Cancer Med"},{"key":"2660_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.imlet.2017.07.015","volume":"190","author":"B Bahrami","year":"2017","unstructured":"Bahrami B, et al. Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett. 2017;190:64\u201383.","journal-title":"Immunol Lett"},{"issue":"1","key":"2660_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-022-01320-5","volume":"15","author":"H Tian","year":"2022","unstructured":"Tian H, et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15(1):132.","journal-title":"J Hematol Oncol"},{"key":"2660_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114449","volume":"188","author":"Y Zi","year":"2022","unstructured":"Zi Y, et al. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Adv Drug Deliv Rev. 2022;188: 114449.","journal-title":"Adv Drug Deliv Rev"},{"key":"2660_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/00914037.2024.2375337","author":"M Summer","year":"2024","unstructured":"Summer M, et al. Exploring the underlying modes of organic nanoparticles in diagnosis, prevention, and treatment of cancer: a review from drug delivery to toxicity. Int J Polym Mater Polym Biomater. 2024. https:\/\/doi.org\/10.1080\/00914037.2024.2375337.","journal-title":"Int J Polym Mater Polym Biomater"},{"issue":"1","key":"2660_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","volume":"9","author":"B Wang","year":"2024","unstructured":"Wang B, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9(1):200.","journal-title":"Signal Transduct Target Ther"},{"key":"2660_CR25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2165\/11314600-000000000-00000","volume":"32","author":"D Wolf","year":"2009","unstructured":"Wolf D, Rumpold H. A benefit-risk assessment of Imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. Drug Saf. 2009;32:1001\u201315.","journal-title":"Drug Saf"},{"issue":"5","key":"2660_CR26","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ctrv.2015.03.005","volume":"41","author":"M Herbrink","year":"2015","unstructured":"Herbrink M, et al. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412\u201322.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"2660_CR27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","volume":"477","author":"V Kumar","year":"2022","unstructured":"Kumar V, et al. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem. 2022;477(4):1261\u201379.","journal-title":"Mol Cell Biochem"},{"key":"2660_CR28","unstructured":"Filppula, A., Role of CYP2C8 in the metabolism of montelukast and Imatinib."},{"issue":"2","key":"2660_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4161\/cc.10.2.14537","volume":"10","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A, et al. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle. 2011;10(2):250\u201360.","journal-title":"Cell Cycle"},{"issue":"2","key":"2660_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1111","volume":"1","author":"MH Elias","year":"2018","unstructured":"Elias MH, et al. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to Imatinib mesylate among chronic myeloid leukemia patients. Cancer Reports. 2018;1(2): e1111.","journal-title":"Cancer Reports"},{"key":"2660_CR31","doi-asserted-by":"crossref","unstructured":"Smith, B.D., Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects. 2011, Oxford University Press. p. 527\u2013529.","DOI":"10.1093\/jnci\/djr073"},{"issue":"5","key":"2660_CR32","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/biomedicines10051158","volume":"10","author":"R Alves","year":"2022","unstructured":"Alves R, et al. Combination of elacridar with Imatinib modulates resistance associated with drug efflux transporters in chronic myeloid leukemia. Biomedicines. 2022;10(5):1158.","journal-title":"Biomedicines"},{"issue":"4","key":"2660_CR33","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/08982104.2015.1117489","volume":"26","author":"SR Paliwal","year":"2016","unstructured":"Paliwal SR, et al. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin. J Liposome Res. 2016;26(4):276\u201387.","journal-title":"J Liposome Res"},{"issue":"19","key":"2660_CR34","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers. 2021;13(19):4820.","journal-title":"Cancers"},{"issue":"12","key":"2660_CR35","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, et al. Off-target effects of BCR\u2013ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012;53(12):2351\u201361.","journal-title":"Leuk Lymphoma"},{"issue":"03","key":"2660_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0033-1343483","volume":"225","author":"A Ulmer","year":"2013","unstructured":"Ulmer A, et al. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model. Klin Padiatr. 2013;225(03):120\u20136.","journal-title":"Klin Padiatr"},{"issue":"2","key":"2660_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.52711\/2231-5691.2024.00026","volume":"14","author":"PNK Sarella","year":"2024","unstructured":"Sarella PNK, et al. Exploring aquasomes: a promising frontier in nanotechnology-based drug delivery. Asian J Pharmaceut Res. 2024;14(2):153\u201361.","journal-title":"Asian J Pharmaceut Res"},{"key":"2660_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/IJN.S442877","volume":"19","author":"X Han","year":"2024","unstructured":"Han X, et al. Biomimetic nano-drug delivery system: an emerging platform for promoting tumor treatment. Int J Nanomed. 2024;19:571\u2013608.","journal-title":"Int J Nanomed"},{"issue":"4","key":"2660_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1504\/IJNT.2006.011179","volume":"3","author":"K Subramani","year":"2006","unstructured":"Subramani K. Applications of nanotechnology in drug delivery systems for the treatment of cancer and diabetes. Int J Nanotechnol. 2006;3(4):557\u201380.","journal-title":"Int J Nanotechnol"},{"issue":"18","key":"2660_CR40","first-page":"4874","volume":"48","author":"X Liang","year":"2023","unstructured":"Liang X, et al. Recent advances in nanocarrier-based drug delivery systems in treatment of rheumatoid arthritis. Zhongguo Zhong yao za zhi= Zhongguo Zhongyao Zazhi= China Journal of Chinese Materia Medica. 2023;48(18):4874\u201383.","journal-title":"Zhongguo Zhong yao za zhi= Zhongguo Zhongyao Zazhi= China Journal of Chinese Materia Medica"},{"key":"2660_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119513","volume":"585","author":"Y Nie","year":"2020","unstructured":"Nie Y, et al. Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm. 2020;585: 119513.","journal-title":"Int J Pharm"},{"key":"2660_CR42","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.2147\/IJN.S466042","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Tumor cell-targeting and tumor microenvironment\u2013responsive nanoplatforms for the multimodal imaging-guided photodynamic\/photothermal\/chemodynamic treatment of cervical cancer. Int J Nanomed. 2024;19:5837\u201358.","journal-title":"Int J Nanomed"},{"issue":"2","key":"2660_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"2660_CR44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10735-024-10223-3","volume":"55","author":"M Summer","year":"2024","unstructured":"Summer M, et al. Revealing the molecular mechanisms in wound healing and the effects of different physiological factors including diabetes, age, and stress. J Mol Histol. 2024;55(5):637\u201354.","journal-title":"J Mol Histol"},{"key":"2660_CR45","unstructured":"Izci, M. Optimizing nanomaterial delivery to solid tumors by physical and pharmaceutical means. In: Oncoforum. 2023."},{"issue":"4","key":"2660_CR46","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s10904-023-02935-y","volume":"34","author":"M Summer","year":"2024","unstructured":"Summer M, et al. Mode of action of biogenic silver, zinc, copper, titanium and cobalt nanoparticles against antibiotics resistant pathogens. J Inorg Organomet Polym Mater. 2024;34(4):1417\u201351.","journal-title":"J Inorg Organomet Polym Mater"},{"key":"2660_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s12011-024-04293-3","author":"H Tahir","year":"2024","unstructured":"Tahir H, et al. Synthesis, characterization, phytochemistry, and therapeutic potential of Azadirachta indica conjugated silver nanoparticles: a comprehensive study on antidiabetic and antioxidant properties. Biol Trace Element Res. 2024. https:\/\/doi.org\/10.1007\/s12011-024-04293-3.","journal-title":"Biol Trace Element Res"},{"key":"2660_CR48","doi-asserted-by":"crossref","unstructured":"Patel JK, Patel AP. Passive targeting of nanoparticles to cancer. Surface modification of nanoparticles for targeted drug delivery, 2019. p. 125\u2013143.","DOI":"10.1007\/978-3-030-06115-9_6"},{"issue":"6","key":"2660_CR49","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/jemt.24509","volume":"87","author":"TA Mughal","year":"2024","unstructured":"Mughal TA, et al. Evaluating the biological (antidiabetic) potential of TEM, FTIR, XRD, and UV-spectra observed berberis lyceum conjugated silver nanoparticles. Microsc Res Tech. 2024;87(6):1286\u2013305.","journal-title":"Microsc Res Tech"},{"key":"2660_CR50","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s00432-014-1767-3","volume":"141","author":"R Bazak","year":"2015","unstructured":"Bazak R, et al. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141:769\u201384.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"19","key":"2660_CR51","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1021\/jm100509v","volume":"53","author":"W Xia","year":"2010","unstructured":"Xia W, Low PS. Folate-targeted therapies for cancer. J Med Chem. 2010;53(19):6811\u201324.","journal-title":"J Med Chem"},{"key":"2660_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.mssp.2024.108419","volume":"178","author":"SS Batool","year":"2024","unstructured":"Batool SS, et al. Enhancing photocatalytic performance of zirconia-based nanoparticles: a comprehensive review of factors, doping strategies, and mechanisms. Mater Sci Semicond Process. 2024;178: 108419.","journal-title":"Mater Sci Semicond Process"},{"issue":"4","key":"2660_CR53","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2317\/0022-8567-96.4.112","volume":"96","author":"M Summer","year":"2024","unstructured":"Summer M, et al. Nanobiopesticides as an alternative and sustainable solution to tackle pest outbreaks. J Kansas Entomol Soc. 2024;96(4):112\u201336.","journal-title":"J Kansas Entomol Soc"},{"issue":"9","key":"2660_CR54","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/nano10091674","volume":"10","author":"C Nieto","year":"2020","unstructured":"Nieto C, Vega MA, Martin del Valle EM. Trastuzumab: more than a guide in HER2-positive cancer nanomedicine. Nanomaterials. 2020;10(9):1674.","journal-title":"Nanomaterials"},{"key":"2660_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2021.102509","volume":"296","author":"B Dutta","year":"2021","unstructured":"Dutta B, Barick K, Hassan P. Recent advances in active targeting of nanomaterials for anticancer drug delivery. Adv Coll Interface Sci. 2021;296: 102509.","journal-title":"Adv Coll Interface Sci"},{"issue":"1","key":"2660_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1527","volume":"11","author":"Y Qiao","year":"2019","unstructured":"Qiao Y, et al. Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscipl Rev Nanomed Nanobiotechnol. 2019;11(1): e1527.","journal-title":"Wiley Interdiscipl Rev Nanomed Nanobiotechnol"},{"issue":"12","key":"2660_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/inorganics12120331","volume":"12","author":"Q Dong","year":"2024","unstructured":"Dong Q, Jiang Z. Platinum\u2013iron nanoparticles for oxygen-enhanced sonodynamic tumor cell suppression. Inorganics. 2024;12(12):331.","journal-title":"Inorganics"},{"key":"2660_CR58","doi-asserted-by":"publisher","first-page":"13339","DOI":"10.2147\/IJN.S486465","volume":"19","author":"D Zhang","year":"2024","unstructured":"Zhang D, et al. Stimulus responsive nanocarrier for enhanced antitumor responses against hepatocellular carcinoma. Int J Nanomed. 2024;19:13339\u201355.","journal-title":"Int J Nanomed"},{"key":"2660_CR59","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.biomaterials.2016.01.061","volume":"85","author":"M Kanamala","year":"2016","unstructured":"Kanamala M, et al. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials. 2016;85:152\u201367.","journal-title":"Biomaterials"},{"issue":"1","key":"2660_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1517\/17425240802662795","volume":"6","author":"B Polyak","year":"2009","unstructured":"Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin Drug Deliv. 2009;6(1):53\u201370.","journal-title":"Expert Opin Drug Deliv"},{"key":"2660_CR61","doi-asserted-by":"publisher","first-page":"103121","DOI":"10.1016\/j.bcab.2024.103121","volume":"57","author":"Z Zulfiqar","year":"2024","unstructured":"Zulfiqar Z, et al. Plant-mediated green synthesis of silver nanoparticles: synthesis, characterization, biological applications, and toxicological considerations: a review. Biocatal Agric Biotechnol. 2024;57:103121.","journal-title":"Biocatal Agric Biotechnol"},{"key":"2660_CR62","doi-asserted-by":"publisher","first-page":"0019","DOI":"10.34133\/cbsystems.0019","volume":"4","author":"M Ye","year":"2023","unstructured":"Ye M, et al. Magnetic microrobots with folate targeting for drug delivery. Cyborg Bionic Syst. 2023;4:0019.","journal-title":"Cyborg Bionic Syst"},{"issue":"9","key":"2660_CR63","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","volume":"124","author":"MA Beach","year":"2024","unstructured":"Beach MA, et al. Polymeric nanoparticles for drug delivery. Chem Rev. 2024;124(9):5505\u2013616.","journal-title":"Chem Rev"},{"issue":"4","key":"2660_CR64","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2174\/156720181304160521004609","volume":"13","author":"K Zhao","year":"2016","unstructured":"Zhao K, et al. Biodegradable polymeric nanoparticles as the delivery carrier for drug. Curr Drug Deliv. 2016;13(4):494\u20139.","journal-title":"Curr Drug Deliv"},{"key":"2660_CR65","doi-asserted-by":"publisher","first-page":"6945","DOI":"10.2147\/IJN.S467876","volume":"19","author":"N Qu","year":"2024","unstructured":"Qu N, et al. Albumin nanoparticle-based drug delivery systems. Int J Nanomed. 2024;19:6945\u201380.","journal-title":"Int J Nanomed"},{"key":"2660_CR66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.biomaterials.2016.04.027","volume":"97","author":"C N\u00fa\u00f1ez","year":"2016","unstructured":"N\u00fa\u00f1ez C, et al. An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 2016;97:34\u201350.","journal-title":"Biomaterials"},{"issue":"9","key":"2660_CR67","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","volume":"13","author":"AA D\u2019souza","year":"2016","unstructured":"D\u2019souza AA, Shegokar R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin Drug Deliv. 2016;13(9):1257\u201375.","journal-title":"Expert Opin Drug Deliv"},{"key":"2660_CR68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijbiomac.2020.02.151","volume":"151","author":"S Bhattacharya","year":"2020","unstructured":"Bhattacharya S. Fabrication and characterization of chitosan-based polymeric nanoparticles of Imatinib for colorectal cancer targeting application. Int J Biol Macromol. 2020;151:104\u201315.","journal-title":"Int J Biol Macromol"},{"issue":"12","key":"2660_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10965-022-03359-x","volume":"29","author":"S Fakhari","year":"2022","unstructured":"Fakhari S, et al. A novel polyamidoamine dendrimer based nano-carrier for oral delivery of Imatinib. J Polym Res. 2022;29(12):523.","journal-title":"J Polym Res"},{"issue":"2","key":"2660_CR70","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00289-023-04760-2","volume":"81","author":"S Kalani","year":"2024","unstructured":"Kalani S, et al. Preparation of alginate magnetic nanoparticles based on Fe3O4 as anticancer drug delivery vehicle: Imatinib loading and in vitro release study. Polym Bull. 2024;81(2):1229\u201348.","journal-title":"Polym Bull"},{"issue":"3","key":"2660_CR71","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/21691401.2016.1175444","volume":"45","author":"L Hasandoost","year":"2017","unstructured":"Hasandoost L, et al. In vitro effect of Imatinib mesylate loaded on polybutylcyanoacrylate nanoparticles on leukemia cell line K562. Artif Cells Nanomed Biotechnol. 2017;45(3):665\u20139.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"8","key":"2660_CR72","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1080\/17470218.2014.945096","volume":"68","author":"MJ Cortese","year":"2015","unstructured":"Cortese MJ, McCarty DP, Schock J. A mega recognition memory study of 2897 disyllabic words. Q J Exp Psychol. 2015;68(8):1489\u2013501.","journal-title":"Q J Exp Psychol"},{"key":"2660_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114412","volume":"202","author":"SL Tsilova","year":"2024","unstructured":"Tsilova SL, et al. Polymeric nanoparticles produced by electrohydrodynamic atomisation for the passive delivery of Imatinib. Eur J Pharm Biopharm. 2024;202: 114412.","journal-title":"Eur J Pharm Biopharm"},{"key":"2660_CR74","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S75962","author":"G Marslin","year":"2015","unstructured":"Marslin G, et al. Delivery as nanoparticles reduces Imatinib mesylate-induced cardiotoxicity and improves anticancer activity. Int J Nanomed. 2015. https:\/\/doi.org\/10.2147\/IJN.S75962.","journal-title":"Int J Nanomed"},{"issue":"3","key":"2660_CR75","doi-asserted-by":"publisher","first-page":"101042831769594","DOI":"10.1177\/1010428317695946","volume":"39","author":"AR James","year":"2017","unstructured":"James AR, et al. Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in Imatinib resistant K562 cells. Tumor Biol. 2017;39(3):1010428317695946.","journal-title":"Tumor Biol"},{"issue":"3","key":"2660_CR76","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1021\/mp5007163","volume":"12","author":"S Labala","year":"2015","unstructured":"Labala S, et al. Layer-by-layer polymer coated gold nanoparticles for topical delivery of Imatinib mesylate to treat melanoma. Mol Pharm. 2015;12(3):878\u201388.","journal-title":"Mol Pharm"},{"issue":"76","key":"2660_CR77","doi-asserted-by":"publisher","first-page":"62214","DOI":"10.1039\/C5RA08501B","volume":"5","author":"M Kamali","year":"2015","unstructured":"Kamali M, et al. Preparation of Imatinib base loaded human serum albumin for application in the treatment of glioblastoma. RSC Adv. 2015;5(76):62214\u20139.","journal-title":"RSC Adv"},{"issue":"1\u20132","key":"2660_CR78","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijpharm.2016.05.008","volume":"507","author":"AM Khan","year":"2016","unstructured":"Khan AM, et al. Investigation of Imatinib loaded surface decorated biodegradable nanocarriers against glioblastoma cell lines: Intracellular uptake and cytotoxicity studies. Int J Pharm. 2016;507(1\u20132):61\u201371.","journal-title":"Int J Pharm"},{"key":"2660_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118508","volume":"568","author":"Y Li","year":"2019","unstructured":"Li Y, Yang B, Zhang X. Oral delivery of Imatinib through galactosylated polymeric nanoparticles to explore the contribution of a saccharide ligand to absorption. Int J Pharm. 2019;568: 118508.","journal-title":"Int J Pharm"},{"key":"2660_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.707319","volume":"9","author":"D Chang","year":"2021","unstructured":"Chang D, et al. Stimuli-responsive polymeric nanoplatforms for cancer therapy. Front Bioeng Biotechnol. 2021;9: 707319.","journal-title":"Front Bioeng Biotechnol"},{"key":"2660_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2022.134569","volume":"433","author":"Z Mazidi","year":"2022","unstructured":"Mazidi Z, et al. Smart stimuli-responsive implantable drug delivery systems for programmed and on-demand cancer treatment: an overview on the emerging materials. Chem Eng J. 2022;433: 134569.","journal-title":"Chem Eng J"},{"issue":"3","key":"2660_CR82","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/pharmaceutics15030775","volume":"15","author":"Z Yu","year":"2023","unstructured":"Yu Z, et al. Smart polymeric nanoparticles in cancer immunotherapy. Pharmaceutics. 2023;15(3):775.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2660_CR83","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1039\/C4MD00348A","volume":"6","author":"B Cortese","year":"2015","unstructured":"Cortese B, et al. Sustained anti-BCR-ABL activity with pH responsive Imatinib mesylate loaded PCL nanoparticles in CML cells. MedChemComm. 2015;6(1):212\u201321.","journal-title":"MedChemComm"},{"issue":"33","key":"2660_CR84","doi-asserted-by":"publisher","first-page":"23886","DOI":"10.1039\/D4RA02439G","volume":"14","author":"S Bhullar","year":"2024","unstructured":"Bhullar S, Goyal N, Gupta S. FericipXT-coated PEGylated rutile TiO2 nanoparticles in drug delivery: in vitro assessment of Imatinib release. RSC Adv. 2024;14(33):23886\u2013901.","journal-title":"RSC Adv"},{"issue":"4","key":"2660_CR85","doi-asserted-by":"publisher","first-page":"e4833","DOI":"10.1002\/aoc.4833","volume":"33","author":"Z Karimi Ghezeli","year":"2019","unstructured":"Karimi Ghezeli Z, Hekmati M, Veisi H. Synthesis of Imatinib-loaded chitosan-modified magnetic nanoparticles as an anti-cancer agent for pH responsive targeted drug delivery. Appl Organometall Chem. 2019;33(4):e4833.","journal-title":"Appl Organometall Chem"},{"issue":"10","key":"2660_CR86","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s10118-022-2726-0","volume":"40","author":"C-Y Wang","year":"2022","unstructured":"Wang C-Y, et al. Intestine enzyme-responsive polysaccharide-based hydrogel to open epithelial tight junctions for oral delivery of Imatinib against colon cancer. Chin J Polym Sci. 2022;40(10):1154\u201364.","journal-title":"Chin J Polym Sci"},{"key":"2660_CR87","doi-asserted-by":"publisher","first-page":"113970","DOI":"10.1016\/j.inoche.2025.113970","volume":"174","author":"A Aslehashemi","year":"2025","unstructured":"Aslehashemi A, Miralinaghi M, Heydarinasab A. A magnetic\/Ph dual-sensitive nanocarrier based on biopolymer-grafted mesoporous Fe3o4@Sio2 for Imatinib delivery: fabrication, characterization, and study of the in-vitro release kinetics. Inorg Chem Commun. 2025;174:113970.","journal-title":"Inorg Chem Commun"},{"key":"2660_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123068","volume":"641","author":"S Siapoush","year":"2023","unstructured":"Siapoush S, et al. Oral targeted delivery of Imatinib by pH responsive copolymer modulates liver fibrosis in the mice model. Int J Pharm. 2023;641: 123068.","journal-title":"Int J Pharm"},{"issue":"8","key":"2660_CR89","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/pat.5337","volume":"32","author":"M Mohammadi Kalakoo","year":"2021","unstructured":"Mohammadi Kalakoo M, et al. Near-infrared triggered drug delivery of Imatinib Mesylate by molybdenum disulfide nanosheets grafted copolymers as thermosensitive nanocarriers. Polym Adv Technol. 2021;32(8):3253\u201365.","journal-title":"Polym Adv Technol"},{"issue":"3","key":"2660_CR90","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1124\/pr.115.012070","volume":"68","author":"P Yingchoncharoen","year":"2016","unstructured":"Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68(3):701\u201387.","journal-title":"Pharmacol Rev"},{"issue":"6","key":"2660_CR91","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1089\/adt.2024.019","volume":"22","author":"S Chauhan","year":"2024","unstructured":"Chauhan S, Nagpal K. Latest delivery advancements of lipid nanoparticles for cancer treatment. Assay Drug Dev Technol. 2024;22(6):340\u201360.","journal-title":"Assay Drug Dev Technol"},{"issue":"17","key":"2660_CR92","doi-asserted-by":"publisher","first-page":"10068","DOI":"10.3390\/ijms231710068","volume":"23","author":"A Chaudhuri","year":"2022","unstructured":"Chaudhuri A, et al. Lipid-based nanoparticles as a pivotal delivery approach in triple negative breast cancer (TNBC) therapy. Int J Mol Sci. 2022;23(17):10068.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2660_CR93","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/pharmaceutics13040520","volume":"13","author":"T Wang","year":"2021","unstructured":"Wang T, et al. Advances in lipid-based nanoparticles for cancer chemoimmunotherapy. Pharmaceutics. 2021;13(4):520.","journal-title":"Pharmaceutics"},{"issue":"5","key":"2660_CR94","doi-asserted-by":"publisher","first-page":"E22106812316387","DOI":"10.2174\/0122106812316387240822075859","volume":"14","author":"A Saha","year":"2024","unstructured":"Saha A, Chauhan SB, Singh I. Targeted drug delivery with lipid-based nanoparticles: innovations for improved cancer therapy. Nanosci Nanotechnol Asia. 2024;14(5):E22106812316387.","journal-title":"Nanosci Nanotechnol Asia"},{"issue":"1","key":"2660_CR95","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/jnt4010004","volume":"4","author":"V Pawar","year":"2023","unstructured":"Pawar V, et al. Responsive nanostructure for targeted drug delivery. J Nanotheranostics. 2023;4(1):55\u201385.","journal-title":"J Nanotheranostics"},{"issue":"2","key":"2660_CR96","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/0122106812266173240327074715","volume":"14","author":"P Patil","year":"2024","unstructured":"Patil P, et al. Development and characterization of imatinib mesylate liposome: for in-vitro anti-cancer activity. Nanosci Nanotechnol Asia. 2024;14(2):79\u201387.","journal-title":"Nanosci Nanotechnol Asia"},{"issue":"2","key":"2660_CR97","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/nano12020250","volume":"12","author":"E Gundogdu","year":"2022","unstructured":"Gundogdu E, et al. An innovative formulation based on nanostructured lipid carriers for Imatinib delivery: pre-formulation, cellular uptake and cytotoxicity studies. Nanomaterials. 2022;12(2):250.","journal-title":"Nanomaterials"},{"issue":"7","key":"2660_CR98","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/pharmaceutics13071086","volume":"13","author":"HA Makeen","year":"2021","unstructured":"Makeen HA, et al. Preparation, characterization, and anti-cancer activity of nanostructured lipid carriers containing Imatinib. Pharmaceutics. 2021;13(7):1086.","journal-title":"Pharmaceutics"},{"issue":"4","key":"2660_CR99","first-page":"1676","volume":"18","author":"MR Molaahmadi","year":"2019","unstructured":"Molaahmadi MR, et al. Lipid nanocapsules for Imatinib delivery: design, optimization and evaluation of anticancer activity against melanoma cell line. Iran J Pharmaceut Res IJPR. 2019;18(4):1676.","journal-title":"Iran J Pharmaceut Res IJPR"},{"key":"2660_CR100","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1007\/s11095-015-1673-7","volume":"32","author":"B Gupta","year":"2015","unstructured":"Gupta B, et al. Modulation of pharmacokinetic and cytotoxicity profile of Imatinib base by employing optimized nanostructured lipid carriers. Pharm Res. 2015;32:2912\u201327.","journal-title":"Pharm Res"},{"issue":"2","key":"2660_CR101","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","volume":"18","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. Expert Opin Drug Deliv. 2021;18(2):205\u201327.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"2660_CR102","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/08982104.2023.2228888","volume":"34","author":"J Huang","year":"2024","unstructured":"Huang J, Chen J. Pharmacokinetics and pharmacodynamic evaluation of hyaluronic acid-modified Imatinib-loaded PEGylated liposomes in CD44-positive Gist882 tumor-bearing mice. J Liposome Res. 2024;34(1):97\u2013112.","journal-title":"J Liposome Res"},{"issue":"3","key":"2660_CR103","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1021\/acs.molpharmaceut.0c01024","volume":"18","author":"R Nisha","year":"2020","unstructured":"Nisha R, et al. Fabrication of Imatinib mesylate-loaded lactoferrin-modified PEGylated liquid crystalline nanoparticles for mitochondrial-dependent apoptosis in hepatocellular carcinoma. Mol Pharm. 2020;18(3):1102\u201320.","journal-title":"Mol Pharm"},{"issue":"2","key":"2660_CR104","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s10876-022-02265-y","volume":"34","author":"K Siram","year":"2023","unstructured":"Siram K, et al. Fabrication of hyaluronic acid surface modified solid lipid nanoparticles loaded with Imatinib mesylate for targeting human breast cancer MCF-7 cells. J Cluster Sci. 2023;34(2):921\u201331.","journal-title":"J Cluster Sci"},{"key":"2660_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jallcom.2020.156604","volume":"849","author":"M Amiri","year":"2020","unstructured":"Amiri M, et al. The magnetic inorganic-organic nanocomposite based on ZnFe2O4-Imatinib-liposome for biomedical applications, in vivo and in vitro study. J Alloy Compd. 2020;849: 156604.","journal-title":"J Alloy Compd"},{"key":"2660_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02838-4","volume":"37","author":"C Li","year":"2020","unstructured":"Li C, Han X. Melanoma cancer immunotherapy using PD-L1 siRNA and Imatinib promotes cancer-immunity cycle. Pharm Res. 2020;37:1\u201310.","journal-title":"Pharm Res"},{"key":"2660_CR107","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.biopha.2016.12.108","volume":"87","author":"P Namdari","year":"2017","unstructured":"Namdari P, Negahdari B, Eatemadi A. Synthesis, properties and biomedical applications of carbon-based quantum dots: An updated review. Biomed Pharmacother. 2017;87:209\u201322.","journal-title":"Biomed Pharmacother"},{"key":"2660_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102117","volume":"61","author":"DM Felix","year":"2021","unstructured":"Felix DM, et al. Graphene quantum dots decorated with Imatinib for leukemia treatment. J Drug Deliv Sci Technol. 2021;61: 102117.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"4","key":"2660_CR109","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/pat.5975","volume":"34","author":"P Asadi","year":"2023","unstructured":"Asadi P, et al. Novel nanoscale vanillin based covalent triazine framework as a novel carrier for sustained release of Imatinib. Polym Adv Technol. 2023;34(4):1358\u201366.","journal-title":"Polym Adv Technol"},{"key":"2660_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-020-02900-1","volume":"37","author":"M Gautam","year":"2020","unstructured":"Gautam M, et al. Stealth polymer-coated graphene oxide decorated mesoporous titania nanoplatforms for in vivo chemo-photodynamic cancer therapy. Pharm Res. 2020;37:1\u201315.","journal-title":"Pharm Res"},{"key":"2660_CR111","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1134\/S1023193521080139","volume":"57","author":"NS Tehrani","year":"2021","unstructured":"Tehrani NS, et al. Hybrid interface based on carboxymethyl cellulose\/N-doped porous reduced graphene oxide for on-demand electrochemical release of Imatinib. Russ J Electrochem. 2021;57:885\u201391.","journal-title":"Russ J Electrochem"},{"issue":"7","key":"2660_CR112","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10856-023-06735-1","volume":"34","author":"M Mashreghi","year":"2023","unstructured":"Mashreghi M, Sabeti B, Chekin F. Magnetite graphene oxide-albumin conjugate: carrier for the Imatinib anticancer drug. J Mater Sci - Mater Med. 2023;34(7):32.","journal-title":"J Mater Sci - Mater Med"},{"issue":"1","key":"2660_CR113","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13065-024-01197-0","volume":"18","author":"M Rezazade","year":"2024","unstructured":"Rezazade M, Ketabi S, Qomi M. Effect of functionalization on the adsorption performance of carbon nanotube as a drug delivery system for Imatinib: molecular simulation study. BMC Chem. 2024;18(1):85.","journal-title":"BMC Chem"},{"key":"2660_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113316","volume":"226","author":"D Marwaha","year":"2023","unstructured":"Marwaha D, et al. Synergistic delivery of Imatinib through multifunctional nano-crystalline capsules, in response to redox environment for improved breast cancer therapy. Colloids Surf, B. 2023;226: 113316.","journal-title":"Colloids Surf, B"},{"issue":"1","key":"2660_CR115","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/10837450.2024.2301763","volume":"29","author":"R Fu","year":"2024","unstructured":"Fu R, et al. Efficient treatment of colon cancer with codelivery of TRAIL and Imatinib by liposomes. Pharm Dev Technol. 2024;29(1):52\u201361.","journal-title":"Pharm Dev Technol"},{"issue":"5","key":"2660_CR116","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/bit.22858","volume":"107","author":"LS Mendon\u00e7a","year":"2010","unstructured":"Mendon\u00e7a LS, et al. Co-encapsulation of anti-BCR-ABL siRNA and Imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng. 2010;107(5):884\u201393.","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"2660_CR117","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/08982104.2020.1720718","volume":"31","author":"J Varshosaz","year":"2021","unstructured":"Varshosaz J, et al. Co-delivery of rituximab targeted curcumin and Imatinib nanostructured lipid carriers in non-Hodgkin lymphoma cells. J Liposome Res. 2021;31(1):64\u201378.","journal-title":"J Liposome Res"},{"issue":"2","key":"2660_CR118","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1039\/C4BM00289J","volume":"3","author":"IE Palam\u00e0","year":"2015","unstructured":"Palam\u00e0 IE, et al. Coupled delivery of Imatinib mesylate and doxorubicin with nanoscaled polymeric vectors for a sustained downregulation of BCR-ABL in chronic myeloid leukemia. Biomater Sci. 2015;3(2):361\u201372.","journal-title":"Biomater Sci"},{"key":"2660_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2022.119789","volume":"362","author":"A Torrik","year":"2022","unstructured":"Torrik A, Zaerin S, Zarif M. Doxorubicin and Imatinib co-drug delivery using non-covalently functionalized carbon nanotube: Molecular dynamics study. J Mol Liq. 2022;362: 119789.","journal-title":"J Mol Liq"},{"issue":"3","key":"2660_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10143","volume":"4","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3): e10143.","journal-title":"Bioeng Transl Med"},{"key":"2660_CR121","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673323270241118103546","author":"S Bhattacharya","year":"2025","unstructured":"Bhattacharya S, et al. Poly lactic co-glycolic acid d-\u03b1-tocopheryl polyethylene glycol 1000 succinate fabricated polyethylene glycol hybrid nanoparticles of Imatinib mesylate for the treatment of glioblastoma multiforme. Curr Med Chem. 2025. https:\/\/doi.org\/10.2174\/0109298673323270241118103546.","journal-title":"Curr Med Chem"},{"issue":"24","key":"2660_CR122","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2217\/nnm-2021-0364","volume":"17","author":"D Ezhilarasan","year":"2022","unstructured":"Ezhilarasan D, Lakshmi T, Mallineni SK. Nano-based targeted drug delivery for lung cancer: therapeutic avenues and challenges. Nanomedicine. 2022;17(24):1855\u201369.","journal-title":"Nanomedicine"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02660-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02660-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02660-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:41:42Z","timestamp":1743554502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02660-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":122,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["2660"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02660-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"116"}}